Not every health app is created equal in the eyes of regulators — and the gap between a wellness app downloaded from a store and a "digital therapeutic" prescribed by a physician is far larger than most patients realize. Understanding that gap matters increasingly as insurers, physicians, and patients navigate a growing category of software that is regulated, evidence-based, and in a meaningful sense, medicine.
What Actually Defines a Digital Therapeutic
The Digital Therapeutics Alliance, the industry's leading trade body, defines digital therapeutics (DTx) as software-driven interventions that deliver evidence-based therapeutic interventions to patients to prevent, manage, or treat a medical disorder — and critically, that have undergone clinical evaluation and, in most cases, FDA authorization as a medical device. This distinguishes DTx sharply from the broader universe of consumer wellness apps, which face essentially no regulatory scrutiny and rarely publish randomized controlled trial data supporting their claims.
A true digital therapeutic typically requires a physician prescription (hence "prescription digital therapeutic," or PDT), is dispensed through a pharmacy-like access code system rather than a public app store, and carries FDA marketing authorization based on clinical trial evidence specific to its therapeutic claim.
The Regulatory Pathway
Most digital therapeutics reach market through the FDA's De Novo or 510(k) pathways as Software as a Medical Device (SaMD), the same broad regulatory framework covering other software-based medical devices. The FDA evaluates the clinical evidence supporting the specific therapeutic claim — not just software safety, but whether the intervention actually produces the clinical outcome it claims to produce, generally demonstrated through a randomized controlled trial comparing the digital intervention against a control condition.
Where the Evidence Is Strongest
The clearest clinical evidence base for digital therapeutics currently exists in three areas: insomnia (cognitive behavioral therapy for insomnia, or CBT-I, delivered digitally, with trial evidence showing effect sizes comparable to in-person CBT-I), substance use disorder (contingency management and relapse-prevention programs showing improved treatment retention), and pediatric ADHD (a digital therapeutic using a video-game-like interface received FDA authorization after trials showed measurable improvement in attention-test performance). Digital therapeutics for chronic conditions including diabetes management and certain anxiety disorders have also accumulated growing trial evidence.
The Reimbursement Bottleneck
Despite regulatory clearance and clinical trial evidence, digital therapeutics have faced a persistent commercial challenge: getting insurers to actually pay for them at a price that sustains the underlying business. Unlike a pharmaceutical, which fits neatly into existing pharmacy benefit and formulary structures, a prescription digital therapeutic often falls into an ambiguous reimbursement category — not quite a drug, not quite a traditional medical device or service. Several major DTx companies have struggled financially or shut down entirely despite strong clinical trial data, largely because payer adoption lagged too far behind regulatory clearance to sustain the business.
What's Changing
Momentum has been building toward a clearer reimbursement pathway: some state Medicaid programs and a growing number of commercial payers have added specific digital therapeutic benefit categories, and industry groups continue to push for federal action establishing a permanent Medicare reimbursement mechanism analogous to the pharmacy benefit. Employer-sponsored health plans have in some cases moved faster than traditional insurers, adding DTx coverage as part of broader digital health benefit packages aimed at reducing downstream costs from undertreated chronic conditions.
Conclusion
Digital therapeutics represent a genuinely new category of medicine — software with the same evidentiary bar and regulatory oversight as a drug, delivered through a smartphone rather than a pill bottle. The clinical evidence for several specific applications is real and growing. Whether the category reaches its full potential now depends less on the science, which has largely been established, and more on whether reimbursement infrastructure catches up to support it.
